PLK1 and non-small cell lung carcinoma: ER NSCLC cell lines that acquired T790M EGFR mutations were more resistant to single-agent PLK1 inhibitors than the parental cell lines were, but the addition of PLK1 inhibition reversed erlotinib resistance.